This article is part of the supplement: Proceedings of the 11th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI): Basic, Epidemiologic, and Clinical Research
Oral presentation
AIDS-associated Kaposi sarcoma in Uganda: response to treatment with highly active antiretroviral therapy and chemotherapy
1 Department of Epidemiology, University of Washington; Seattle, Washington, USA
2 Department of Laboratory Medicine, University of Washington; Seattle, Washington, USA
3 Deparment of Medicine, University of Washington; Seattle, Washington, USA
4 Program in Biostatistics, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
5 Program in Vaccine and Infectious Disease Institute, Fred Hutchinson Cancer Research Center, Seattle, Washington; USA
6 Uganda Cancer Institute, Kampala, Uganda
7 Infectious Disease Institute, Kampala, Uganda
Infectious Agents and Cancer 2009, 4(Suppl 2):O5 doi:10.1186/1750-9378-4-S2-O5
Published: 17 June 2009First paragraph (this article has no abstract)
Highly active antiretroviral therapy (HAART) alone or in combination with systemic chemotherapy has been shown to be effective therapy for AIDS-associated Kaposi sarcoma (KS) in resource-rich countries. It is not known whether HAART or chemotherapy regimens available in resource-poor regions are effective in areas where KS is hyperendemic and typically more aggressive. Therefore, we conducted a retrospective cohort study to evaluate clinical response among patients with AIDS-associated KS treated with HAART alone or in combination with chemotherapy in Uganda.